Reginald Seeto - 09 Jun 2021 Form 4 Insider Report for CareDx, Inc. (CDNA)

Role
President and Chief Executive Officer, Director
Signature
/s/ Reginald Seeto
Issuer symbol
CDNA
Transactions as of
09 Jun 2021
Net transactions value
-$1,060,753
Form type
4
Filing time
11 Jun 2021, 17:51:33 UTC
Previous filing
09 Jun 2021
Next filing
25 Jun 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CDNA Common Stock Options Exercise $168,898 +6,093 +4.3% $27.72 148,727 09 Jun 2021 Direct F1
transaction CDNA Common Stock Options Exercise $158,483 +5,833 +3.9% $27.17 154,560 09 Jun 2021 Direct F1
transaction CDNA Common Stock Options Exercise $116,685 +4,792 +3.1% $24.35 159,352 09 Jun 2021 Direct F1
transaction CDNA Common Stock Sale $1,504,819 -16,718 -10% $90.01 142,634 09 Jun 2021 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CDNA Employee Stock Option (right to buy) Options Exercise $0 -6,093 -6.8% $0.000000 83,434 09 Jun 2021 Common Stock 6,093 $27.72 Direct F1, F3
transaction CDNA Employee Stock Option (right to buy) Options Exercise $0 -5,833 -18% $0.000000 26,167 09 Jun 2021 Common Stock 5,833 $27.17 Direct F1, F4
transaction CDNA Employee Stock Option (right to buy) Options Exercise $0 -4,792 -12% $0.000000 35,208 09 Jun 2021 Common Stock 4,792 $24.35 Direct F1, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $90.00 to $90.15, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased or sold at each separate price.
F3 25% of the shares subject to the option vested on November 26, 2019 and 1/48th of the shares subject to the option vest monthly thereafter.
F4 1/4th of the shares subject to the option vested on February 4, 2019 and 1/48th of the shares subject to the option vest monthly thereafter.
F5 1/4th of the shares subject to the option vested on January 29, 2021 and 1/48th of the shares subject to the option vest monthly thereafter.

Remarks:

President and Chief Executive Officer